BRAF and cancer: Similarly, we know that the BRAF V600E mutation is highly prevalent in papillary thyroid cancers, with its reported frequency varying from 30 up to 85% among studies [9]; however, when looking at the cancers with Bethesda category III and IV cytology, we find a lower prevalence of BRAF mutations and a higher presence of other mutations such as RAS mutations [10].